Summit Therapeutics Inc. (SMMT)
$
18.81
+0.44 (2.34%)
Key metrics
Financial statements
Free cash flow per share
-0.3660
Market cap
13.7 Billion
Price to sales ratio
0
Debt to equity
0.0282
Current ratio
3.7960
Income quality
0.2947
Average inventory
0
ROE
-3.1115
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Summit Therapeutics Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines aimed at treating infectious diseases in the United States and Latin America. The firm has a clinical program primarily dedicated to combating Clostridioides difficile infection (CDI), with ridinilazole as its lead product candidate. This orally administered small molecule antibiotic is currently in Phase III clinical trials for CDI treatment. In addition to ridinilazole, Summit Therapeutics offers SMT-738, targeting multidrug-resistant infections, particularly those caused by carbapenem-resistant Enterobacteriaceae, as well as the DDS-04 series designed for the potential treatment of Enterobacteriaceae-related infections. Despite its innovative advancements, the company reported a net loss of -$221,315,000.00 indicating challenges in its operations. The gross profit ratio stands at 0.00 showcasing the efficiency of its production and sales processes. Moreover, the EBITDA ratio of 0.00 highlights operational efficiency, even as the company faces selling, general, and administrative expenses of $60,527,000.00 reflecting its operational overhead costs. The company’s stock is traded under the symbol 'SMMT' in the market, providing investors with insight into its financial performance. The stock is affordable at $18.89 catering to budget-conscious investors who are looking for opportunities in the biopharmaceutical space. Additionally, the stock enjoys a high average trading volume of 3,908,424.00 which indicates strong liquidity and investor interest. With a mid-range market capitalization of $14,002,964,140.00 the company is regarded as a steady performer within its sector. As a key player in the Biotechnology industry, Summit Therapeutics contributes significantly to the overall market landscape, driving innovation and growth. Belonging to the Healthcare sector, it plays a crucial role in advancing solutions to pressing health challenges, continuing to pave the way for new treatments amid its ongoing clinical trials and research initiatives.
Is Summit Therapeutics Inc. (SMMT) a good investment?
Investing in Summit Therapeutics Inc. (SMMT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Summit Therapeutics Inc. (SMMT)'s stock forecast?
Analysts predict Summit Therapeutics Inc. stock to fluctuate between $15.55 (low) and $36.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Summit Therapeutics Inc.'s market capitalization?
As of 2025-12-04, Summit Therapeutics Inc.'s market cap is $14,002,964,140, based on 744,442,538 outstanding shares.
How does Summit Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Summit Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Summit Therapeutics Inc. (SMMT) stock?
To buy Summit Therapeutics Inc. (SMMT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SMMT. Place an order (Market, Limit, etc.).
What is the best time to invest in Summit Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Summit Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.31 | Growth: -68.69%.
Where can I find Summit Therapeutics Inc.'s investor relations reports?
Visit https://www.summittxinc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Summit Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Summit Therapeutics Inc. stock?
All-time high: $36.91 (2025-04-24) | All-time low: $0.66 (2022-12-02).
What are the key trends affecting Summit Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript
fool.com
Summit Therapeutics plans to file for a key FDA approval by the end of this year. The drugmaker is betting that the FDA will change its mind on guidance already handed down.
seekingalpha.com
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
seekingalpha.com
Akeso stands out as a diversified Chinese biotech with strong licensing deals, a robust pipeline, and growing revenues from multiple approved therapies. Unlike SMMT, AKESF benefits from milestone payments, retains Chinese commercialization rights, and faces less development risk from single-asset dependence. SMMT's commercialization ability is questionable, with leadership concerns, cash burn, and the loss of key partnerships like Pfizer undermining its prospects.
seekingalpha.com
I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying. SMMT's Ivonescimab targets non-small cell lung cancer through its dual Anti-PD-1 plus Anti-VEGF mechanism, with the potential to outperform the benchmarks. While there's a lot of uncertainty regarding sales and even more to earnings, valuation suggests significant upside if SMMT captures just 4% market share by 2033.
seekingalpha.com
Summit Therapeutics Inc. ( SMMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Clara Dong Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon.
seekingalpha.com
Summit Therapeutics Inc. ( SMMT ) UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right, everyone. Thank you for joining us.
247wallst.com
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.
fool.com
Summit Therapeutics' ivonescimab continues to ace phase 3 studies against approved drugs. The investigational cancer medicine could eventually become one of the world's best-selling therapies.
zacks.com
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
See all news
